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Background: The clinical importance of airway colonisation by the fungus Exophiala dermatitidis in patients with cystic ﬁbrosis (CF) is unclear.
We have previously shown that E. dermatitidis frequently colonises the airways of patients with CF. The aims of the present study were to
determine whether patients who are colonised by E. dermatitidis have detectable fungal antigens in the circulation, develop anti-fungal antibodies,
and show signs of inﬂammation and impaired respiratory function.
Methods:We collected sputum and serum samples consecutively from 98 sputum-producing patients with CF aged more than 12 years. The serum
samples were subjected to bacterial and fungal culturing and analyses for fungal antigens and inﬂammatory factors.
Results: E. dermatitidis was recovered from 17 (17%) patients, the same isolation rate as for Aspergillus fumigatus. There were no difference
regarding the levels of β-glucan in the sera from E. dermatitidis culture-positive and culture-negative patients with CF. Serological analysis
revealed signiﬁcantly higher levels of IgG antibodies to E. dermatitidis cell wall fragments in the E. dermatitidis culture-positive patients. Patients
with higher level of E. dermatitidis IgG antibodies were more often colonised with non-tuberculous Mycobacteria, and less often with
Staphylococcus aureus. The increased levels of IgG antibodies directed against E. dermatitidis were positively associated with higher white blood
cell counts, increased erythrocyte sedimentation rate, pancreatic insufﬁciency, intravenous antibiotic treatment, and they were negatively
associated with respiratory function (FEV1 % predicted). Overall, 4/17 Exophiala-positive patients were diagnosed as having symptomatic
infection with E. dermatitidis and were treated with broad-spectrum azoles.
Conclusion: E. dermatitidis triggers antibody production and may cause signiﬁcant airway infection in patients with cystic ﬁbrosis.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Exophiala; Cystic ﬁbrosis; IgG antibodies; Fungal infection1. Introduction
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http://dx.doi.org/10.1016/j.jcf.2013.12.007;lishedinfections in patients with cystic fibrosis (CF), contributing to a
remarkable increase in life expectancy [1]. Staphylococcus
aureus, Pseudomonas aeruginosa, Haemophilus influenzae, and
Burkholderia cepacia are considered to be the major causes of
respiratory infections in patients with CF [1,2]. In contrast, the
clinical importance of fungal colonisation of the airways is less
clear. Fungi are ubiquitous in nature and are commonly found in
soil, plants, and decomposing organic material [3]. Repeated use
of antibacterial agents, corticosteroid treatment, and exposure toby Elsevier B.V. All rights reserved.
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respiratory tract of patients with CF, which may lead to true
fungal infections [4–6].
Most studies of CF have focused on Aspergillus fumigatus,
a mould that causes a variety of infectious and allergic diseases
depending on the immune status or pulmonary structure of the
host [7–10]. Inhaled fungal elements are deposited in the
alveoli of the lungs, and in an appropriate host, the fungal
hyphae may invade the lung tissues. Depending on the immune
status of the host, the growth of the fungus might be restricted to
the airways, it may invade the basement membrane, or it may
invade blood vessels, causing haemorrhage and eventual fungal
dissemination [11]. A. fumigatus is known to cause allergic
bronchopulmonary aspergillosis (ABPA), microinvasive bron-
chitis, and severe invasive infection after lung transplantation
of patients with CF [12–14]. The persistence of Aspergillus
infection has been suggested to be associated with more
pulmonary exacerbations and reduced lung function [8,12].
However, other filamentous fungi, such as Pseudoallescheria
boydii (Scedosporium apiospermum), also chronically colo-
nise the airways of patients with CF. These fungi are resistant
to almost all currently available antifungal drugs [15]. Candida
species are isolated with high frequency from the sputum
samples of patients with CF [13]. Pancreatic insufficiency
and concomitant colonisation with Pseudomonas have been
described as the main factors that predict colonisation by
Candida albicans of patients with CF [16,17]. However, the
definitive role of Candida species in causing disease in patients
with CF remains unclear. In this regard, the establishment of the
International Society of Human and Animal Mycology (ISHAM)
working group for fungal infections in CF represents a step
forward in understanding the role of fungal colonisation and
infection in patients with CF.
We have previously reported that the black yeast Exophiala
dermatitidis is a frequent coloniser of the respiratory tract in
patients with CF in Sweden [18]. When the sputum samples of
patients with CF or other respiratory diseases and those of lung
transplant recipients were monitored for E. dermatitidis over a
6-month period, we found that the fungus was present only in
the samples from the patients with CF. The identification of
E. dermatitidis requires the use of a selective culture medium
that contains erythritol–chloramphenicol, to inhibit the growth
of bacteria, in combination with incubation times of up to
3 weeks [18]. However, in the aforementioned study, we were
unable to determine the clinical importance and pathogenicity
of this fungus in patients with CF. The aim of the present study
was to investigate the inflammatory responses to and potential
pathogenicity of E. dermatitidis in CF in a cross-sectional
study conducted over 1 year. To this end, we set up an ELISA
for the detection of antibody responses to E. dermatitidis.
Furthermore, we investigated whether fungal cell wall antigens
could be detected in the blood samples of colonised patients
and whether inflammatory parameters and respiratory function
were related to colonisation with E. dermatitidis. We also
retrieved data from the patient database, and retrospectively
reviewed the clinical records of patients who had shown
positive cultures for E. dermatitidis.2. Patients and methods
2.1. Patients and clinical data
In this cross-sectional study conducted over 1 year, sputum-
producing patients with CF who were N12 years of age were
invited to participate at the time of their comprehensive yearly
assessment at the Gothenburg CF Centre. Patients who had
undergone lung transplantation were excluded. The Local
Ethics Committee in Gothenburg, Sweden (Ethical Approval
no. 433–08) approved the study protocol, and all the patients
gave informed consent. A large proportion of the patients at our
centre had participated in the previous study [18].
Among the clinical data retrieved from the patient database
was information on age, CFTR genotype, pancreatic function,
presence of diabetes mellitus, pulmonary function expressed as
the forced expiratory volume in one second (FEV1) percent
predicted, white blood cell counts (WBC), erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), titres of total IgG and
IgE in serum, and the number of intravenous (i.v.) antibiotic
courses received during the previous year.2.2. Bacterial and fungal cultures
Three sputum samples were collected from each patient for
the identification of bacteria, mycobacteria, and fungi, respectively.
Sputum samples were analysed at the Department of Clinical
Bacteriology, Sahlgrenska University Hospital, as previously
described [18]. Briefly, after treatment with pancreatin, the
sputum samples were plated onto horse blood agar, Streptococcus
agar, Haemophilus agar, Sabouraud agar, and erythritol–
chloramphenicol agar. Cultures were incubated at 30 °C and
examined daily for fungal growth over a period of 10 days,
followed by weekly monitoring for a total of 4 weeks; cultures
were inspected after 2 days for growth of bacteria. Sputum
samples were also cultured on Löwenstein–Jensen media for
the detection of Mycobacteria after decontamination with
sodium hydroxide and oxalic acid and incubation at 37 °C for
56 days. Serum samples were stored at −70 °C until used.2.3. Anti-fungal antibody titres
Cell wall fragments of E. dermatitidis were prepared as
described earlier [19]. E. dermatitidis strain CBS 20735
(Centraalbureau voor Schimmelcultures, Utrecht, The Nether-
lands) was grown in Sabouraud dextrose broth on a shaker at
37 °C for 2 days. Yeast cells were harvested by centrifugation
(1200 ×g) and washed three times with PBS. After washing,
the cell pellet was re-suspended in an equal volume of distilled
water. Glass beads (0.5 mm in diameter) were added to the cell
suspension at a volume ratio of 1:3. The mixture was shaken 10
times for 30 s in a sonicator on ice. The supernatant was collected
and the glass beads were washed several times with distilled
water until the washing solution became clear. The supernatant
and washing solution were pooled. The cell wall fraction was
sedimented at 1200 ×g for 10 min, washed three times with
Table 1
Bacterial and fungal species isolated from the sputum specimens of patients
with cystic fibrosis (n = 98).
Microorganism No. Total %
Fungi
Exophiala dermatitidis 17 17
Aspergillus fumigatus 17 17
Candida species 56 57
Scedosporium apiospermum 1 1
Paecilomyces variotii 1 1
Fusarium species 1 1
Bacteria
Staphylococcus aureus 39 40
Pseudomonas aeruginosa 39 40
Stenotrophomonas maltophilia 12 12
Mycobacterium species 13 13
Haemophilus influenzae 4 4
Burkholderia species 4 4
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freeze-dried.
Microplate wells were coated with 100 μl of 50 μg/ml
E. dermatitidis cell wall fragments in 50 mM Na2CO3 buffer
(pH 9.3). The plates were incubated at room temperature (r.t.)
for 2 h and then kept at 4 °C overnight. The plates were rinsed
once with PBS, and then 100 μl of blocking buffer (BF; 1%
BSA, 0.05% Tween-20 in PBS) was added to each well and
incubated for 1 h at r.t. The plates were rinsed once with 0.05%
Tween-20 in PBS (PBS-T). Patient sera, diluted 1/1000 in BF,
were added to each well and incubated for 2 h at r.t. The plates
were rinsed three times with PBS-T between incubations.
Biotinylated goat-anti-human IgG (Sigma-Aldrich, St. Louis,
MO) diluted 1/5000 in BF was added and the plates were
incubated at r.t. overnight. Then, 100 μl of 1/10,000-diluted
alkaline phosphatase-conjugated extravidin (Sigma-Aldrich)
was added and incubated at r.t. for 60 min. Para-nitrophenyl
phosphate (100 μl) at a concentration of 1 mg/ml in diethanol
amine buffer (pH 9.8) was added to each well. The optical
absorbance at 405 nm was read after 60 min of incubation.
The titres of IgG antibodies to C. albicans and A. fumigatus
were determined using the SERION ELISA C. albicans and
A. fumigatus IgG kits (Virion/Serion, Wurzburg, Germany),
according to the manufacturer's instructions.
2.4. Fungal antigens in serum
The concentration of β-glucan in sera was determined using
the Glucatell kit (Associates of Cape Cod, East Falmouth, MA),
with minor modifications to the manufacturer's instructions.
Serum samples were diluted 1/10 in pyrogen-free water and
heat-inactivated at 75 °C for 10 min, to inactivate proteins
present in the serum that might interfere with the test. The sera
and standards (50 μl) were added to microplate wells, followed
by 50 μl of the lysate reagent. The plate was incubated at 37 °C
for 30 min. Thereafter, the azo-coupling reagents were added to
the wells. The optical absorbance of the samples was read at
560 nm. A standard curve was plotted, and the concentration of
β-glucan (pg/ml) was determined for each sample. A cut-off
value for a positive β-glucan level was set at ≥80 pg/ml, as
recommended by the manufacturer.
The levels of galactomannan in sera were determined using the
Platelia Aspergillus enzyme immunoassay (Bio-Rad, Marnes-la-
Coquette, France). An optical density (OD) index ≥0.5 was
considered to be positive.
2.5. Statistical analysis
The microbiological and clinical data were analysed using
the multivariate technique of Orthogonal Projection to Latent
Structures (OPLS), using the SIMCA-P software (Umetrics
AB, Umeå, Sweden) [20]. OPLS is a regression extension of
principal component analysis (PCA) in which variables termed
“score vectors” that co-vary with a selected Y-variable, for
example, levels of anti-E. dermatitidis IgG antibodies in serum,
are identified. OPLS was used to relate score vectors (microbial
agents isolated from the CF sputum samples, inflammatoryparameters, and clinical data) to the chosen Y-variable (serum
IgG antibody against E. dermatitidis). The GraphPad Prism
ver. 5.00 software (GraphPad Software, La Jolla, CA) was
used for the univariate statistical analysis. To compare fungal
antigen and anti-fungal IgG antibodies with various fungi in
the CF serum, one-way ANOVA followed by Bonferroni's
multiple comparison was used. Correlations were analysed by
the Spearman's rank correlation test. A P-value of b0.05 was
considered to be statistically significant.
3. Results
3.1. Patients
Between October 2009 and October 2010, we consecutively
enrolled 98/107 (92%) eligible patients, representing 70%
(98/141) of the total CF population at the centre during that
period. Lung-transplanted patients (n = 7) and children younger
than 12 years (n = 27) were excluded. The patients had the
following characteristics: mean age, 27 ± 11 years; pancreatic
insufficiency, 85%; male, 53%; and mean lung function assessed
as forced expiratory volume in one second (FEV1), 76% of
predicted. Of the patients, 49% were homozygous and 41% were
heterozygous for the ΔF508 mutation.
3.2. Pathogenic microorganisms in sputum
Fungi were isolated from the sputum samples of the majority
(70%) of the patients (Table 1). Candida species (n = 56),
especially C. albicans (43/56, 76%) and Candida dubliniensis
(13/56, 23%), were the most frequently detected, followed by the
black yeast E. dermatitidis (17%) and the mould A. fumigatus
(17%). The emerging fungi S. apiospermum, Paecilomyces
variotii, and Fusarium species were isolated from one patient
each (Table 1). Candida was recovered to a greater extent from
patients who were positive for E. dermatitidis (82%, P = 0.029).
S. aureus, P. aeruginosa, Stenotrophomonas maltophilia, and
non-tuberculous mycobacteria (n = 13) were the most common
bacteria isolated from the sputum samples (Table 1).
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The patients who were culture-positive for E. dermatitidis had
detectable levels of E. dermatitidis-specific IgG in their serum
samples. Thus, the IgG antibody titres to E. dermatitidis cell wall
antigens were significantly higher in the E. dermatitidis culture-
positive patients with CF, as compared with patients who were
colonised with other fungal species and patients who were not
colonised with fungi (Fig. 1a). Similarly, patients who showed
positive for A. fumigatus in their sputum cultures had signifi-
cantly higher levels of anti-Aspergillus IgG than did culture-
negative patients (P = 0.046) (Fig. 1b). In contrast, the levels of
serum IgG antibodies to C. albicans cell wall antigens were not
different for patients who were colonised with C. albicans,
colonised with other fungal species, or not colonised with fungi,
respectively (Fig. 1c).
3.4. Fungal antigens in sera from patients with CF
One-third of the patients (29/98) had elevated levels of the
pan-fungal cell wall antigen β-glucan in the serum. However,
the β-glucan concentrations in the sera of patients who were
culture-positive for fungi in their sputum did not differ
significantly from those patients who were culture-negative
for fungi (Fig. 2). None of the patients showed a positive serum
test for galactomannan, which is a cell wall antigen of Aspergillus,Fig. 1. Titres of IgG antibodies in the sera of patients with CF (n = 98) directed aga
indicates the IgG antibody level in the serum of a single patient. Patients are g
culture-negative (−) for any other fungus. The horizontal line indicates the mediandespite the fact that 17% of the patients were colonised by
Aspergillus.
3.5. Clinical correlates of seroconversion to E. dermatitidis
Multivariate analysis of the clinical and microbiological data
revealed that increased levels of IgG antibodies to E. dermatitidis
were associated with the isolation of Exophiala from sputum
samples, as was expected (Fig. 3). Moreover, patients who had
seroconverted to E. dermatitidis tended to be colonised with
non-tuberculous mycobacteria and P. aeruginosa and had fewer
S. aureus in their sputum samples (Fig. 3). Clinical features that
were positively associated with increased levels of IgG antibodies
to E. dermatitidis were pancreatic insufficiency and the number
of intravenous (i.v.) antibiotic courses received during the
preceding year, whereas a negative association with FEV1 %
predicted was observed. Finally, the patients who had sero-
converted to E. dermatitidis tended to have more inflamma-
tion, e.g., had higher white blood cell counts (WBC) and an
increased ESR in the serum.
3.6. Antifungal treatment of E. dermatitidis-colonised patients
For information regarding the administration of anti-fungal
therapy, we retrospectively reviewed the clinical records of 17
patients who had shown positive sputum tests for E. dermatitidis.inst: (a) E. dermatitidis; (b) Aspergillus; and (c) Candida species. Each symbol
rouped based on whether their sputum samples were culture-positive (+) or
level for the group.*, P b 0.05, ****, P b 0.0001.
Fig. 2. Concentrations of β-glucan in the sera of patients with CF (n = 98),
grouped based on positive or negative sputum fungal culture status for
E. dermatitidis, Aspergillus and Candida species. Patients colonised with two or
three different fungi are included in two or three groups, respectively. Three
patients were colonised with E. dermatitidis, A. fumigatus, and Candida. Three
patients were colonised with E. dermatitidis and A. fumigatus. Fourteen patients
were colonised with E. dermatitidis and Candida, and eight patients were
colonised with A. fumigatus and Candida.
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fungal cell wall antigens in serumwere not available at the time of
diagnosis of clinically significant infection with E. dermatitidis,
they could not be used to guide treatment decisions. However,
analyses of the β-glucan levels in sera had been performed
outside of the study protocol for clinical purposes for two of the
four patients who received treatment (Table 2).
Patient 1 was a 22-year-old male who was homozygous for the
ΔF508 mutation and who had normal lung function, CF-relatedFig. 3. Multivariate analysis with OPLS was used to relate score vectors (microbia
clinical data) to the chosen Y-variable (serum IgG antibody against E. dermatitidi
anti-E. dermatitidis IgG levels. The negative bars show variables that are negativel
confidence intervals. The asterisks indicate statistically significant differences f
anti-E. dermatitidis IgG antibodies in the serum.*, P b 0.05; **, P b 0.01; ***, P bdiabetes, a previous liver transplant due to CF-related liver disease,
and chronic infectionwith P. aeruginosa. He received 4months of
treatment with itraconazole owing to a blood-tinged cough and
increased sputum production that did not respond to i.v. antibiotics
directed against Pseudomonas. The symptoms gradually subsided
during antifungal treatment. Following the recurrence of the
infection symptoms, elevated β-glucan levels (N400 pg/ml), and
repeated positive cultures for E. dermatitidis, he has recently been
successfully treated for 3 months with posaconazole, after which
the symptoms have subsided and subsequent sputum cultures have
been negative for fungi, while his β-glucan levels have remain
elevated.
Patient 2 was a 34-year-old male who was homozygous for
the ΔF508 mutation and had CF-related diabetes, severe
gastro-oesophageal reflux disease, FEV1 40% of predicted,
chronic infection with S. maltophilia, and sputum cultures that
were consistently positive for E. dermatitidis and intermittent-
ly positive for Candida and A. fumigatus. The regular therapy
included low-dose oral corticosteroids and intermittent intrave-
nous, inhaled, and oral antibiotics. Treatment with voriconazole
was initiated when antibiotics directed against bacteria did not
relieve the symptoms of airway infection, but this regimen was
stopped after 4 months owing to limited clinical effect, elevated
liver function tests, and adverse effects on vision. The sputum was
cleared temporarily of E dermatitidis. Surgery with fundoplication
was performed subsequently, resulting in some improvement of
airway symptoms.
Patient 5, who was a 34-year-old female with the ΔF508/
unknown genotype, pancreatic insufficiency, allergic asthma,
FEV1 40% of predicted, and various pathogens cultured from the
sputum (S. aureus, Serratia marcescens, Candida species, and
Mycobacterium avium), was repeatedly positive for E. dermatitidisl agents isolated from the CF sputum samples, inflammatory parameters, and
s). The positive bars indicate that the variables are positively associated with
y associated with levels of E. dermatitidis-specific IgG. The whiskers indicate
rom the univariate analyses (Spearman) between parameters and levels of
0.001; ****, P b 0.0001.
Table 2
Characteristics of patients with cystic fibrosis who showed positive for Exophiala dermatitidis (ED) in sputum cultures collected at their annual control.
Patient ID Age Gender CF complications FEV1 %
pred.
No. of ED + cultures
in preceding year a
Other
pathogens b
Total serum IgE
level; kU/l
Anti-ED IgG in serum;
absorbance at 405 nm
β-glucan;
pg/ml c
1 d 22 M DM, Liver Tx 111 N5 PA 12 0.766 263
2 d 34 M Reflux, DM 40 N5 C, AF, SM 2.4 0.765 130
3 28 M 87 1 C, AF, PA, MAb 6.2 0.566 b50
4 34 F 65 1 C, PA 11 0.547 202
5 d 34 F AA 40 N5 C, SA, MAv 42 0.540 85
6 24 M AA 95 4 C 75 0.531 293
7 18 F ABPA, DM 70 N5 C, MAb 1200 0.491 b50
8 36 F DM 95 N5 PA, SA 23 0.480 94
9 d 12 M ABPA 88 2 C, SM 650 0.480 69
10 29 F 66 2 C, BC, MAb 90 0.444 82
11 47 M DM 52 2 C, PA, SA 0.416 89
12 28 M AA 70 1 C, AF, PA 190 0.386 59
13 17 M DM, LD 87 1 C, SA, SM 130 0.368 26
14 28 F 110 1 C, Mav 28 0.343 60
15 20 F 80 1 C, PA 21 0.279 b50
16 22 F 101 3 C, SA 6.6 0.260 b50
17 26 F 123 2 Sapio, SA 11 0.190 53
All patients were pancreatic-insufficient.
AA, allergic asthma; FEV1 % pred., forced expiratory volume in one second; ABPA, allergic bronchopulmonary aspergillosis; DM, CF-related diabetes mellitus; LD,
CF-related liver disease; Tx, transplanted.
a Total number of positive cultures.
b Other pathogens cultured from sputum at the annual control: ED, Exophiala dermatitidis; C, Candida species; AF, Aspergillus fumigatus; Sapio, Scedosporium
apiospermum; PA, Pseudomonas aeruginosa; SA, Staphylococcus aureus; SM, Stenotrophomonas maltophilia; BC, Burkholderia cepacia; MAb, Mycobacterium
abscessus; MAv, Mycobacterium avium.
c A level of β-glucan b80 pg/ml was considered to be normal.
d Received antifungal therapy (see text for details).
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unexplained airway symptoms that did not respond as expected to
the usual antibiotics. The treatment was stopped already after 1
month due to intolerable adverse effects with emesis, and the
clinical effect was difficult to evaluate. Sputum cultures revealed
only sparse growth of E. dermatitidis at treatment termination.
Patient 9, who was a 12-year-old boy with theΔF508/R764X
genotype, developed multiple filled cavities in the lungs, as
detected by high-resolution computer tomography (Fig. 4).
S. maltophilia,Candida and E. dermatitidiswere cultured from
his sputum sample, but there was no A. fumigatus. His serum
level of β-glucan was 217 pg/ml. He underwent successful
treatment 12 months earlier for allergic bronchopulmonary
aspergillosis (ABPA) and had previously been intermittently
infected with and received treatment for P. aeruginosa and
S. maltophilia, respectively. Treatment was initiated, initially
with 14 days of i.v. amphotericin B, followed by posaconazole for
7 months, which resulted in radiological and clinical improve-
ment (Fig. 5). The patient has since responded well to two shorter
periods of treatment with posaconazole for worsening clinical
symptoms, recurrence of E. dermatitidis in the sputum, and
increased levels of β-glucan.
Two patients had β-glucan levels N200 pg/ml but lacked
clinical evidence of fungal infection (Table 2). Both of these
patients have seasonal allergic asthma requiring inhaled
steroids. One of them (Patient 6) has mild lung disease and
seldom requires antibiotic treatment, while the other (Patient 4)
requires 4–5 antibiotic courses each year.4. Discussion
In contrast to C. albicans and A. fumigatus, which are
well-known colonisers of the airways of patients with CF,
E. dermatitidis has been reported infrequently in this context. The
prevalence of E. dermatitidis in our current cross-sectional study
was 17%, ranking it as the second most commonly isolated (by
culturing) fungal species from the CF airways [18]. However,
Baxter et al. [21] have reported that the detection of fungal DNA
in sputum samples from patients with CF is more sensitive than
culturing. The prevalence ofE. dermatitidis in CF varies from 5%
in Germany to 10% in Austria and 15% in Belgium [6,22]. These
different prevalences may reflect genetic heterogeneity, differ-
ences in life style and age of the patients included in the studies or
differences in the culture methods used for the CF sputum
samples [22]. The high prevalence of E. dermatitidis in the home
environment may facilitate colonisation of the respiratory tract by
this fungus. Zalar et al. [23] reported that 56% of the dish-washers
in their study were colonised by E. dermatitidis and Exophiala
phaeomuriformis. In addition, black yeasts have been isolated
from wet rooms and kitchens [24,25].
The most frequently isolated yeast in the present study was
C. albicans (56%), which is in agreement with reports in the
literature [22,26]. A. fumigatus was the most commonly
isolated filamentous fungus (17%) in the present study, and
this is a lower prevalence than has been reported in other
studies [22,27]. In their study, Masoud-Landgraf et al. [22]
isolated A. fumigatus from 79% of the sputum samples of
ab
Fig. 4. (a) Chest radiograph and (b) high-resolution computed tomography scan
of Patient 9 at the time of initiation of anti-fungal therapy. The arrows indicate
mucous-filled cavities located in the right-lower and left-upper lobes.
Fig. 5. Computed tomography image of Patient 9 performed 9 months after start
of treatment.
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that study, whereas the present study included patients who
were N12 years of age. Nagano et al. [28] reported a lower rate
of A. fumigatus isolation (5.2%) from patients with CF in the
UK who were N18 years of age.
In the present study, we show that E. dermatitidis and
A. fumigatus induce antibody responses in patients with CF.
E. dermatitidis or A. fumigatus culture-positive patients had
significantly higher levels of IgG antibodies to E. dermatitidis
or A. fumigatus than those patients who were culture-negative
for these fungi. There were no differences in the serum levels
of IgG antibody to C. albicans between patients who were
culture-positive and those who were culture-negative for
Candida. These findings indicate that the acquired immune
system does come into contact with Exophiala species and
A. fumigates, such that antigen-presenting cells present fungal
elements to antigen-specific B cells, which subsequently
expand and produce isotype-switched IgG antibodies. To our
knowledge, this is the first study to describe specific IgGantibodies directed against E. dermatitidis in a large cohort of
patients with CF. A case report published 20 years ago
described a child with CF who developed pneumonia that was
attributed to E. dermatitidis, in part because specific antibodies
were detected using an indirect immunofluorescence assay
[29].
Increased levels of IgG antibodies to E. dermatitidis were
significantly correlated with higher rates of colonisation with
other pathogenic microorganisms, pancreatic insufficiency, more
days on i.v. antibiotics, and poorer respiratory function. A
plausible explanation for the association of Exophiala serocon-
version with greater impairment of lung function and the growth
of certain pathogens in the sputum is the increased antibiotic load
that results from repeated iv courses or prolonged treatment with
inhaled or multiple oral antibiotics. As a consequence, alterations
to the airway microflora that benefit fungal growth occur; this
may not be true for shorter courses of antibiotic treatment [30].
Non-tuberculous mycobacteria and E. dermatitidis were preva-
lent in the sputum samples of patients with CF. Both of these
organisms are ubiquitous in the environment, which means that
exposure is common [30]. The relationship between antibacterial
therapy and E. dermatitidis in patients with CF has not been
studied previously. We found a positive association between the
presence of anti-E. dermatitidis IgG antibodies and i.v. antibiotic
treatment. However, the relationship between bacterial infection
that required i.v. antibiotic treatment and fungal colonisation or
infection has been shown in two previous studies [8,31]. Baxter et
al. reported a significant reduction in the presence Aspergillus
species following short-term antibacterial therapy [31].
We found that patients who had seroconverted to Exophiala
had more inflammation, reflected in their higher WBC and ESR,
as compared with seronegative patients. The interpretation of
these results is difficult due to the unspecific nature of these
inflammatory markers (WBC and ESR). In addition, these
inflammation markers have been studied in the blood samples
but not in the sputum samples obtained from the patients with CF.
Since colonisation with E. dermatitidiswas associated with lower
FEV1 % and concomitant colonisation with other bacteria, this
398 N. Kondori et al. / Journal of Cystic Fibrosis 13 (2014) 391–399finding is most probably not related exclusively to colonisation
with E. dermatitidis.
Detection of β-glucan, which is a component of the cell wall
of clinically important fungi, is used as a diagnostic aid for
patients with suspected invasive fungal infection. It is unclear
as to how the fungal antigens are released into the circulation.
It has been suggested that fungal antigens diffuse freely
through the endothelial lining of the pulmonary capillaries and/or
that angioinvasive growth of fungus is required for the antigens to
be deposited in the bloodstream [11]. In the present study, no
association was observed between the presence of E. dermatitidis
in sputum samples and the levels of β-glucan in the sera of the
patients with CF. In contrast, β-glucan levels were positively
associated with seroconversion to Exophiala. This indicates that
patients with higher loads of E. dermatitidis are more likely to
seroconvert and to have detectable β-glucan in their serum.
However, β-glucan is a pan-fungal antigen, so a positive
β-glucan test cannot distinguish the causative fungal agent.
Among the 17 Exophiala-colonised patients, seven were
positive for β-glucan (N80 pg/ml), and three of these seven
patients received antifungal treatment for suspectedE. dermatitidis
infection. However, a fourth patient (Patient 9), who had a
β-glucan concentration below the cut-off level at the time of
culture, subsequently developed pulmonary infection with infil-
trates, decreased lung function, and increased β-glucan levels in
the serum: this patient responded well to extended antifungal
treatment. Overall, the concentrations ofβ-glucan in the sera of the
patients with CF were high, even in those patients whose airways
were not colonised with fungi. This may reflect leakage of fungal
elements across the mucosal lining of the gastrointestinal tract into
the blood. It is well-known that the gastrointestinal tract is also
affected in CF [32]. The diagnostic value of an optimal cut-off
value for β-glucan for the assessment of fungal infections in CF
needs to be further evaluated.
The lack of measurements of inflammatory markers and
fungal DNA in the sputum samples are major limitations in the
present study. Patients who are intermittently positive for
fungi may be diagnosed as being negative while still revealing
signs of immunological responses, with positivity for β-glucan
and Exophiala IgG. All patients who were culture-positive for
E. dermatitidis were reviewed retrospectively, to assess the
clinical significance of the laboratory tests.
In summary, E. dermatitidis appears to be an opportunistic
pathogen that might contribute to inflammation and cause
significant pulmonary infection in patients with CF. Our case
studies demonstrate that some patients show clinical im-
provement when the fungus is cleared though the adminis-
tration of antifungal drugs directed against Exophiala.
Therefore, E. dermatitidis should be viewed as an emerging
opportunistic pathogen in the CF setting.Acknowledgements
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